Plasma glutathione S-transferase pi 1-1 AND alpha 1-1 levels in patients with bladder cancer.
Plasma glutathione S-transferase pi 1-1 AND alpha 1-1 levels in patients with bladder cancer.
复制标题
膀胱癌患者血浆谷胱甘肽 S-转移酶 pi 1-1 和 α 1-1 水平。
作者：
C. Berendsen;T. Mulder;W. Peters
目的
人膀胱移行细胞癌和许多胃肠道肿瘤通常含有大量的解毒酶谷胱甘肽S-转移酶pi（GSTP 1 -1）。在胃肠道癌、肺癌或头颈癌患者的血清和血浆中发现了升高的GST 1 -1水平。据报道，GSTP 1 -1和谷胱甘肽S-转移酶α（GSTA 1 -1）在15例膀胱癌患者中的10例（67%）中升高。我们评价了50例膀胱癌患者治疗前后血浆肿瘤标志物GSTP 1 -1和GSTA 1 -1的作用。
材料和方法
从膀胱癌患者的血液中取样于乙二胺四乙酸管中。采用双抗体夹心酶联免疫吸附法测定血浆GSTA 1 -1和GSTP 1 -1水平。
结果
50例膀胱癌患者中分别有2例（4%）和14例（28%）血浆GSTA 1 -1和GSTP 1 -1水平高于正常参考上限。在治疗前和治疗后收集的配对血浆样品中，未观察到血浆GSTA 1 -1或GSTP 1 -1的显著降低。
结论
与早期报道相反，只有有限数量的膀胱癌患者血浆GSTA 1 -1或GSTP 1 -1升高，肿瘤切除后没有降低。这些发现反对使用GSTP 1 -1或GSTA 1 -1作为膀胱癌的血浆标志物。
PURPOSE
Transitional cell carcinomas of the human bladder and many gastrointestinal tumors often contain high amounts of the detoxification enzyme glutathione S-transferase pi (GSTP1-1). Elevated levels of GSTP1-1 have been found in serum and plasma from patients with gastrointestinal, lung or head and neck cancer. GSTP1-1 and glutathione S-transferase alpha (GSTA1-1) have been reported to be increased in 10 of 15 patients (67%) with bladder cancer. We evaluate the role of GSTP1-1 and GSTA1-1 as plasma tumor markers in 50 patients with bladder cancer before and after treatment.
MATERIALS AND METHODS
Blood from patients with bladder cancer was sampled in ethylenediaminetetraacetic acid tubes. Plasma GSTA1-1 and GSTP1-1 were measured using the sensitive and specific sandwich enzyme-linked immunosorbent assay.
RESULTS
Respective plasma GSTA1-1 and GSTP1-1 levels were above the upper normal reference limit in 2 (4%) and 14 (28%) of the 50 patients with bladder cancer. No significant decrease in plasma GSTA1-1 or GSTP1-1 was noted in matched pairs of plasma samples collected before and after treatment.
CONCLUSIONS
In contrast to earlier reports, only a limited number of patients with bladder cancer had increased plasma GSTA1-1 or GSTP1-1, which did not decrease after tumor resection. These findings argue against the use of GSTP1-1 or GSTA1-1 as plasma markers for bladder cancer.